Clinical validation of a biopsy-based six-gene signature prognostic for aggressive prostate cancer.

ABSTRACT:

Objectives

This study aimed to clinically validate the six-gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue.

Methods

MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T-stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C-indexes from Cox proportional hazard regression models.

Results

Biopsy MCRS was significantly prognostic (p</

SUBMITTER: Krzyzanowska A 

PROVIDER: S-EPMC11771492 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature